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OBJECTIVES: Patients with type 2 diabetes are known
to make increased use of health-care resources, but the
impact of specific macro and microvascular complica-
tions on costs is unclear. Here we use regression based
methods to estimate the immediate and long-term impact
of six diabetes-related complications on hospital costs,
using data from the UKPDS, a large (n  5102) and long-
term (median duration 10.3 years) clinical trial.
METHODS: Data on the occurrence and precise timing
of pre-defined diabetes-related complications, and on all
hospitalisations with associated specialties, lengths of
stay, and procedures, were collected routinely for all pa-
tients during the trial. Panel data regression analysis was
used to estimate the immediate impact (i.e. in the year
event occurred) and long-term impact (i.e. in each subse-
quent year) of the following six diabetes-related compli-
cations on hospital costs: fatal and non fatal myocardial
infarction (n  828); fatal and non-fatal stroke (n 
271); heart failure (n  166); angina (n  319); blindness
in one eye (n  166); amputation (n  67). Hospital
costs were calculated using national average specialty-
specific costs per inpatient day, expressed in 1999 £s UK.
RESULTS: All six diabetes-related complications had a
statistically significant impact on hospital costs. In the
year in which the complication occurred, diabetes-related
complications were associated with increased hospital
costs ranging from £995 for loss of sight in one eye to
£5478 for an amputation. In subsequent years the annual
magnitude of this effect ranged from 13% to 33% of the
costs in the initial year.
CONCLUSIONS: Regression analysis on a large and
well-validated, patient-specific data set yields plausible
empirically based estimates of the hospital cost conse-
quences of diabetes-related complications. These will be
of use to other economists and health service researchers,
particularly those interested in assessing the costs of dia-
betes and the cost-effectiveness of interventions within a
modeling framework.
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BOTTOM UP VERSUS TOP DOWN COST 
ESTIMATES FOR TYPE 2 DIABETES
Koopmanschap MA, Redekop K, Niessen L
Erasmus University, Rotterdam, Netherlands
OBJECTIVES: To compare top down and bottom up
cost estimates of direct health-care costs for diabetes type
2 in the Netherlands.
METHODS: For the top down cost estimates we used
comprehensive Dutch national age and sex-specific cost
of illness estimates for diabetes and diseases related to di-
abetes complications. Costs for diabetes type 2 were sep-
arated by age (age 35 and older) and by prevalence rates
for types 1 and 2. The costs of complications were esti-
mated using costs and prevalence rates for cardiovascular
diseases, neuropathy, nephropathy and retinopathy, com-
bined with relative risks for these complications in pa-
tients with diabetes type 2. The bottom up costs were es-
timated using a sample of 1371 type 2 diabetes patients
for whom their GP reported the total medical consump-
tion related to diabetes and its complications during the
previous six months.
RESULTS: Total medical costs for diabetes type 2 in
1998 were Euro 567 mln according to the bottom up es-
timate versus Euro 519 mln for the top down estimate, or
less than 10 % difference in cost. The costs for in hospital
care, ambulatory care and equipment were very compa-
rable. The cost of medication was higher according to the
bottom up study. The bottom up study identified a larger
amount of cardiovascular and lipid lowering drugs. Both
costing methods show that complications, especially car-
diovascular, are responsible for a substantial portion of
total health-care costs.
CONCLUSIONS: For diabetes type 2 it was demon-
strated that using comprehensive top down disease costs
combined with sound epidemiological data on complica-
tions, can yield valid cost estimates that are quite compa-
rable with bottom up cost estimates.
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OBJECTIVE: To develop a model for predicting hospital
costs in patients with diabetes mellitus.
METHODS: We have previously shown that, in compar-
ison with standard cost models, better prediction can be
achieved with a two-part model that independently pre-
dicts risk of hospitalization and cost of hospitalization. In
this analysis we have developed a three-part model by
adding mortality to the original two-part model, because
patients who die do not necessarily incur hospital costs in
the year of death. Furthermore we have extended the
three-part model to an autoregression model. Age, gen-
der, any hospitalization in the last year, log-hospital costs
in the last year and log-mean costs over all previous years
were included in the model. A Bayesian forecasting
method was used to obtain a predictive distribution of
costs in the next year.
RESULTS: We identified 5672 type 2 diabetic patients in
the Tayside area and analyzed annual hospital costs be-
tween 1988 and 1995. The fitted three-part model showed
that increasing age was associated with increasing mor-
tality and with increasing costs per hospital episode.
However, age was not associated with the risk of hospi-
talization. Cost of hospitalization in previous years was
positively associated with risk of hospitalization (OR 
1.51/ln(mean costs), CI  1.48, 1.53) and mortality (OR 
1.22/ln(mean costs), CI  1.19,1.25). An example of
Bayesian cost forecasting showed that for female patients
aged 50 to 59, increasing hospital costs in the previous
year increased the probability of having a high-cost hos-
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pital admission in the next year but paradoxically it also
increased the probability of having zero hospital costs due
to increased risk of death without hospitalization.
CONCLUSIONS: Costs incurred in previous years can be
used to predict costs and outcomes in the future. This dy-
namic three-part model clarifies the relationship between
risk of hospitalization, cost of hospitalization and mortality.
INFECTIOUS DISEASE
IN1
ESTIMATING THE POTENTIAL HEALTH GAIN 
AND COST CONSEQUENCES OF INTRODUCING 
A PRE-SCHOOL DTPA PERTUSSIS BOOSTER 
INTO THE UK CHILD VACCINATION SCHEDULE
Stevenson M1, Beard S1, Finn A2, Brennan A1
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Sheffield, UK
OBJECTIVE: To establish the likely health and cost im-
pacts of a pre-school booster vaccination for Bordetella
pertussis, when added to existing UK primary vaccina-
tion schedules assuming that a diphtheria, tetanus, and
acellular pertussis, (DTPa) booster would replace the cur-
rent diphtheria and tetanus (DT) booster.
METHODS: A transition state model of pertussis infec-
tion in a closed population representative of England and
Wales, comprised of eight age bands with susceptible, in-
fected and immune population sub-groups. Herd-immu-
nity was explicitly modeled. Epidemiological service use
and cost data were sourced from routine statistics, pub-
lished literature and, where necessary, clinical estimates.
The number of pertussis cases, hospitalizations and
deaths were forecast for a five-year period. Quality of life
gains were not explicitly calculated.
RESULTS: Introducing a pre-school pertussis booster
and achieving 84% coverage is predicted to cost an addi-
tional £14.32m over a five-year period, assuming £5
marginal cost between DTPa and DTP or £8.60m assum-
ing a £3 marginal cost. Offset against this are the cost of
reduced hospitalizations and GP consultations, which are
expected to total between £4.21m and £4.60m. The re-
turn on this investment would be a reduction in up to
1700 hospitalizations, between 5000 and 27,000 pertus-
sis cases depending on the level of under-reporting and
assuming a vaccine waning period, and one infant death.
CONCLUSIONS: The introduction of a pre-school
booster is predicted to significantly reduce the number of
hospitalizations and pertussis cases contracted. The esti-
mated marginal cost of this strategy is £10m over a five-
year period, assuming a £5 difference between DTP and
DTPa or £4m, were the difference only £3.
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Viral respiratory infection (VRI) is the most commonly oc-
curring illness in man, imposing considerable burden on
patients and on society. However, to date, no formal study
of the economic impact of VRI has been performed.
OBJECTIVES: To rigorously quantify the economic im-
pact of viral respiratory disease (VRI) in the US in terms
of health-care resource utilization (direct costs) and pro-
ductivity losses (indirect costs).
METHODS: Publicly available databases including the
US Census, National Health Interview Survey (NHIS),
the Medical Expenditure Panel Survey (MEPS) and the
National Ambulatory Medical Care Survey (NAMCS)
were used. From these databases, projections regarding
population characteristics, physician and emergency-room
encounters, prescription and over-the-counter drug utiliza-
tion, and productivity losses related to VRI were made.
Data obtained from primary epidemiological research and
prospective randomized clinical trials were used to esti-
mate the incidence of VRI in the general population and
the rate of secondary clinical complications associated
with VRI.
RESULTS: Nearly 500 million episodes of VRI occur an-
nually in the US alone. Direct costs associated with VRI
are estimated to be $16.8 billion annually and are broken
down as follows: physician visits, $6 billion; complica-
tions, $3.8 billion; prescription and over-the-counter medi-
cations, $4.8 billion. Indirect costs for employed individu-
als approximate $7.6 billion per year. Physician encounters
via a telephone and the internet, productivity losses incurred
by caregivers (i.e. parent) of VRI-infected individuals, and
costs associated with diminished productivity while at work
or home were not included, suggesting that this projection
of total VRI costs—$25 billion annually in the US alone—is
very likely an under-estimate.
CONCLUSIONS: Viral respiratory infections impose a
significant clinical and economic burden to society, ap-
proaching or surpassing the aggregate costs of many
common chronic diseases. The resultant clinical and cost
ramifications attributable to this common acute condi-
tion warrants increased attention from health-care pro-
viders and policy makers.
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OBJECTIVE: Pneumococcal conjugate vaccine for in-
fants has recently been found effective against meningitis,
